Press Releases Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
9.03 ^USD	+5.99%		+4.03%	+146.72%

Apr. 15	Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target	MT
Mar. 18	Mind Medicine Inc. announced that it has received $75 million in funding from Deep Track Capital, LP, Commodore Capital	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MindMed to Present at Upcoming May Medical Conferences	Apr. 25	BU
MindMed to Present at Upcoming April Medical Conferences	Apr. 02	BU
MindMed Announces Voluntary Delisting from Cboe Canada	Apr. 01	BU
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference	Mar. 11	BU
Mind Medicine MindMed : Investor Presentation - MM120 for Generalized Anxiety Disorder Conference Call and Webcast	Mar. 07	PU
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement	Mar. 07	BU
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder	Mar. 07	BU
Thinking about buying stock in Minim, GameSquare, Laser Photonics, Geron, or Mind Medicine?	Mar. 01	PR
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120	Mar. 01	BU
MindMed Reports 2023 Financial Results and Business Updates	Feb. 28	BU
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update	Feb. 22	BU
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference	Feb. 07	BU
Canadian Investment Regulatory Organization Trading Halt - MMED.WR	Jan. 08	AQ
MindMed Announces Business Update and Anticipated Milestones for 2024	Jan. 08	BU
Mind Medicine MindMed : Investor Presentation - MM-120 for Generalized Anxiety Disorder Results Call	Dec. 15	PU
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder	Dec. 14	BU
Canadian Investment Regulatory Organization Trading Halt - MMED.WA	Dec. 11	AQ
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights	Nov. 02	BU
Canadian Investment Regulatory Organization Trading Halt - MMED.WS	23-10-30	AQ
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update	23-10-26	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Press Releases

Filters